L
Linda D. Shortliffe
Researcher at Stanford University
Publications - 100
Citations - 4678
Linda D. Shortliffe is an academic researcher from Stanford University. The author has contributed to research in topics: Urinary system & Kidney. The author has an hindex of 32, co-authored 99 publications receiving 4294 citations. Previous affiliations of Linda D. Shortliffe include University of California, San Francisco & Lucile Packard Children's Hospital.
Papers
More filters
Journal ArticleDOI
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
Keith Syson Chan,Inigo Espinosa,Mark P. Chao,David J. Wong,Laurie Ailles,Max Diehn,Harcharan Gill,Joseph C. Presti,Howard Y. Chang,Matt van de Rijn,Linda D. Shortliffe,Irving L. Weissman +11 more
TL;DR: The isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary human bladder cancer is described, based on the expression of markers similar to that of normal bladder basal cells, which effectively distinguishes muscle-invasive bladder cancer with worse clinical prognosis from non-muscle-in invasive (superficial) cancer.
Journal ArticleDOI
Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.
W. G. Harker,Frederick J. Meyers,Fuad S. Freiha,John M. Palmer,Linda D. Shortliffe,John F. Hannigan,K. M. McWhirter,Frank M. Torti +7 more
TL;DR: CMV is an effective regimen for patients with metastatic transitional cell carcinoma of the bladder and prolonged disease-free survival may result from a CR to this regimen.
Journal ArticleDOI
Pediatric Urinary Tract Infections
TL;DR: Patients with documented evidence of renal scarring should be followed up for signs of renal deterioration and hypertension and treatment should be tailored to the pathogen as dictated by the urine culture sensitivities.
Journal ArticleDOI
Three differentiation states risk-stratify bladder cancer into distinct subtypes.
Jens Peter Volkmer,Jens Peter Volkmer,Debashis Sahoo,Robert K. Chin,Philip Levy Ho,Chad Tang,Antonina V. Kurtova,Stephen B. Willingham,Senthil K. Pazhanisamy,Humberto Contreras-Trujillo,Theresa A. Storm,Yair Lotan,Andrew H. Beck,Benjamin I. Chung,Ash A. Alizadeh,Guilherme Godoy,Seth P. Lerner,Matt van de Rijn,Linda D. Shortliffe,Irving L. Weissman,Keith Syson Chan +20 more
TL;DR: The data indicate that bladder cancer can be subclassified into three subtypes, on the basis of their differentiation states: basal, intermediate, and differentiated, where only the most primitive tumor cell subpopulation within each subtype is capable of generating xenograft tumors and recapitulating downstream populations.
Journal ArticleDOI
Treatment of urinary incontinence by the periurethral implantation of glutaraldehyde cross-linked collagen.
TL;DR: This investigation shows that glutaraldehyde cross-linked collagen can be injected into the urinary tract to correct urinary incontinence without observable or measurable morbidity.